Clinical trial
Azacitidine and Entinostat in Treating Patients With Recurrent Advanced…
NCT00387465 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00387465 |
|---|---|
| Title | Azacitidine and Entinostat in Treating Patients With Recurrent Advanced Non-Small Cell Lung Cancer |
| Official title | A Phase I/II Study of Entinostat in Combination With 5-Azacytidine in Patients With Recurrent Advanced Non-Small Cell Lung Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Recurrent Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer |
| Intervention type | Drug |
| Interventions | Azacitidine 30mg/m2, Entinostat, Azacitidine 40mg/m2 |
| Enrollment | 94 |
| Start date | Aug 1, 2006 |
| Primary completion | May 1, 2014 |
| Completion | Nov 1, 2014 |
| First posted | Oct 13, 2006 |
| Last update posted | May 9, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: